Modality
ADC
MOA
PCSK9i
Target
PRMT5
Pathway
Amyloid
NMOSD
Development Pipeline
Preclinical
~Feb 2023
→ ~May 2024
Phase 1
Aug 2024
→ Jan 2025
Phase 1Current
NCT06870048
1,391 pts·NMOSD
2024-08→2025-01·Recruiting
1,391 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-201.2y agoPh2 Data· NMOSD
Trial Timeline
Q42025
P1/2
Recruit…
Catalysts
Ph2 Data
2025-01-20 · 1.2y ago
NMOSD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06870048 | Phase 1/2 | NMOSD | Recruiting | 1391 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 |